Candel Therapeutics (CADL) Cash from Operations: 2020-2023
Historic Cash from Operations for Candel Therapeutics (CADL) over the last 3 years, with Dec 2023 value amounting to -$7.4 million.
- Candel Therapeutics' Cash from Operations fell 7.80% to -$7.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$34.2 million, marking a year-over-year decrease of 8.99%. This contributed to the annual value of -$27.0 million for FY2024, which is 21.09% up from last year.
- As of Q4 2023, Candel Therapeutics' Cash from Operations stood at -$7.4 million, which was up 15.74% from -$8.8 million recorded in Q3 2023.
- In the past 5 years, Candel Therapeutics' Cash from Operations ranged from a high of -$1.5 million in Q3 2020 and a low of -$10.8 million during Q1 2023.
- Its 3-year average for Cash from Operations is -$7.3 million, with a median of -$7.1 million in 2022.
- Per our database at Business Quant, Candel Therapeutics' Cash from Operations slumped by 358.07% in 2021 and then increased by 6.14% in 2023.
- Quarterly analysis of 4 years shows Candel Therapeutics' Cash from Operations stood at -$3.4 million in 2020, then plummeted by 53.34% to -$5.2 million in 2021, then slumped by 31.44% to -$6.9 million in 2022, then decreased by 7.80% to -$7.4 million in 2023.
- Its last three reported values are -$7.4 million in Q4 2023, -$8.8 million for Q3 2023, and -$7.2 million during Q2 2023.